ReviewNeural regeneration research2014
Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.
Review in Neural regeneration research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Unlocking the epigenetic symphony: histone acetylation's impact on neurobehavioral change in neurodegenerative disorders.Epigenomics · 2024Review
- Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders.CNS & neurological disorders drug targets · 2024Article
- The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.Neural regeneration research · 2020Review
- Repulsive guidance molecules lock growth differentiation factor 5 in an inhibitory complex.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Marine-Derived Natural Compounds for the Treatment of Parkinson's Disease.Marine drugs · 2019Review
- Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair.International journal of molecular sciences · 2018Review
- Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.Nano letters · 2017Article
- Heparin, Heparan Sulphate and the TGF-β Cytokine Superfamily.Molecules (Basel, Switzerland) · 2017Review
- Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.Neuronal signaling · 2017Review
- Back to the tubule: microtubule dynamics in Parkinson's disease.Cellular and molecular life sciences : CMLS · 2017Review
- Current Experimental Studies of Gene Therapy in Parkinson's Disease.Frontiers in aging neuroscience · 2017Review
- Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2016Review
- A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.Neurotoxicity research · 2016Article
- Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.Neuroscience · 2016Article
- Neurotrophic factor therapy for Parkinson's disease: past, present and future.Neural regeneration research · 2016Article
- Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice.International journal of molecular sciences · 2016Review
- Protocol for evaluation of neurotrophic strategies in Parkinson's disease-related dopaminergic and sympathetic neuronsJournal of biological methods · 2016Article
- TLR4 Signaling in MPP⁺-Induced Activation of BV-2 Cells.Neural plasticity · 2016Article
- Drug and gene delivery across the blood-brain barrier with focused ultrasound.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroprotection and neuroregeneration are two of the most promising disease-modifying therapies for the incurable and widespread Parkinson's disease. In Parkinson's disease, progressive degeneration of nigrostriatal dopaminergic neurons causes debilitating motor symptoms. Neurotrophic factors play important regulatory roles in the development, survival and maintenance of specific neuronal populations. These factors have the potential to slow down, halt or reverse the loss of nigrostriatal dopaminergic neurons in Parkinson's disease. Several neurotrophic factors have been investigated in this regard. This review article discusses the neurodevelopmental roles and therapeutic potential of three dopaminergic neurotrophic factors: glial cell line-derived neurotrophic factor, neurturin and growth/differentiation factor 5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.